Genentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver ...

The FDA has approved a surgically implanted pulmonary heart valve for pediatric patients with congenital pulmonary valve disease.  | The FDA has approved a surgically implanted pulmonary heart valve ...

Vaxcyte has seen its stock jump after the biotech’s 31-valent pneumococcal vaccine candidate went head-to-head with Pfizer’s Prevnar 20 and Merck & Co.’s Capvaxive in a phase 3 contest. The biotech ...

Genmab has linked an antibody-drug conjugate (ADC) to median progression-free survival (PFS) of 9.5 months, leading TD Cowen ...

Click Therapeutics has nabbed FDA approval for its digital therapeutic Motivista, which now becomes the first authorized ...

Eli Lilly has been pushing at an open door by tacking on $870 million in biobucks to its existing collaboration with Gate Bioscience. | Eli Lilly has been pushing at an open door by tacking on $870 ...

Sanofi is paying Regeneron $1 billion upfront to collaborate on four early-stage im | Sanofi is paying Regeneron $1 billion ...

Eli Lilly has tied its amylin-Zepbound combination treatment eloraTZP to 23.3% average weight loss in patients struggling ...

Merck touted a win for its anti-TL1A antibody in a phase 2b trial in patients with moderate to severe hidradenitis ...

Eli Lilly has shared detailed data from a phase 3 retatrutide trial, revealing that more than one-third of patients on the ...

A phase 3 trial of Boehringer Ingelheim’s survodutide in people with obesity and Type 2 diabetes has met its co-primary ...

When Xaira Therapeutics debuted in 2024 with a gobsmacking $1 billion in funding, a natural expectation would have been for a ...